Pembrolizumab-associated Chronic Rhinosinusitis: A New Endotype and Management Considerations

Overview

Journal Int Forum Allergy Rhinol

Specialties Allergy & Immunology
Otorhinolaryngology

Date 2023 Jun 15

PMID 37317899

Authors

Taylor C Standiford

Neil N Patel

Amritpal Singh

Grant Gochman

Tara Jamie Wu

Adil I Daud

Andrew N Goldberg

Affiliations

Soon will be listed here.

Abstract

Patients treated with pembrolizumab experience an increase in paranasal sinus inflammation Use of topical triamcinolone in carboxymethylcellulose is a treatment option for such patients.

Citing Articles

Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.

Tzoumpa S, Villette B, Granel-Brocard F, Dutriaux C, Memmi A, Jeudy G Immunotherapy. 2024; 16(16-17):1029-1037.

PMID: 39268924 PMC: 11492644. DOI: 10.1080/1750743X.2024.2399498.

Immune Checkpoint Inhibitor (ICI) Induced Sinonasal Disease: Review of Literature and FDA Database.

Pak K, Nadeem W, Lee V, Tang D, Wu A Ann Otol Rhinol Laryngol. 2024; 133(10):893-897.

PMID: 39115140 PMC: 11529109. DOI: 10.1177/00034894241273192.